| Literature DB >> 31898156 |
Chenfeng He1, Kosuke Kawaguchi2, Masakazu Toi1.
Abstract
Cell DNA is continuously attacked by endogenous and exogenous agents, which causes DNA damage. During long-term evolution, complex defense systems for DNA damage repair are formed by cells to maintain genome stability. Defects in the DNA damage repair process may lead to various diseases, including tumors. Therefore, DNA damage repair systems have become a new anti-tumor drug target. To date, a number of inhibitors related to DNA damage repair systems have been developed, particularly for tumors with BRCA1 and BRCA2 mutations. Poly (ADP-ribose) polymerase inhibitors developed by synthetic lethality are widely used in individualized tumor therapy. In this review, we briefly introduce the mechanisms underlying DNA damage repair, particularly in breast cancer, and mainly focus on new treatments targeting the DNA damage repair pathway in breast cancer.Entities:
Keywords: BRCA1/2; DNA damage repair; PARP inhibitor; Synthetic lethality
Mesh:
Substances:
Year: 2020 PMID: 31898156 DOI: 10.1007/s12282-019-01038-2
Source DB: PubMed Journal: Breast Cancer ISSN: 1340-6868 Impact factor: 4.239